Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc.（PLX）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · PLX · 截至 2026年6月9日
活动摘要
买入笔数
1
P-Purchase only
卖出笔数
1
近12个月
买卖比
1.00
Buy/Sell (by trades)
整体情绪
Protalix BioTherapeutics, Inc.内部人在过去近12个月买卖活动混合。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
PLX 季度内部人买卖趋势
PLX 内幕交易卖出 · PLX 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · PLX CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
PLX 高管卖出股份 · PLX 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Dec 19, 2025 | Bashan Dror PRESIDENT AND CEO · Director | Purchase | 56,000 | $101K | Form 4 |
| Nov 18, 2025 | Bar-Shalev Amos Director | Sale | 168 | $314 | Form 4 |
| Sep 3, 2025 | Forster Eliot Director | Award | 7,500 | — | Form 4 |
| Sep 3, 2025 | Melincoff Gwen A Director | Award | 7,500 | — | Form 4 |
| Sep 3, 2025 | Boudes Pol F Director | Award | 7,500 | — | Form 4 |
| Sep 3, 2025 | Elze Christian Director | Award | 7,500 | — | Form 4 |
| Sep 3, 2025 | Schwartz Aharon Director | Award | 7,500 | — | Form 4 |
| Sep 3, 2025 | Ben Zvi Shmuel Director | Award | 7,500 | — | Form 4 |
| Sep 3, 2025 | Bar-Shalev Amos Director | Award | 7,500 | — | Form 4 |
| Sep 3, 2025 | Naos Yaron Sr. VP, Operations | Award | 25,000 | — | Form 4 |
| Sep 3, 2025 | Bashan Dror PRESIDENT AND CEO · Director | Award | 195,000 | — | Form 4 |
| Jun 10, 2025 | Schwartz Aharon Director | Purchase | 129,000 | $206K | Form 4 |
| Sep 23, 2024 | Rubin Eyal Sr. VP and CFO | Award | 99,010 | — | Form 4 |
| Apr 1, 2024 | Bashan Dror PRESIDENT AND CEO · Director | Award | 263,960 | — | Form 4 |
| Oct 19, 2023 | Bashan Dror PRESIDENT AND CEO · Director | Purchase | 16,129 | $23K | Form 4 |
| Oct 19, 2023 | Bashan Dror PRESIDENT AND CEO · Director | Purchase | 48,387 | $68K | Form 4 |
| Aug 15, 2023 | Bashan Dror President and CEO · Director | Award | 800,000 | — | Form 4 |
| Aug 15, 2023 | Rubin Eyal Sr. VP and CFO | Award | 201,903 | — | Form 4 |
| Aug 15, 2023 | Hayon Yael VP, Research & Development | Award | 35,115 | — | Form 4 |
| Aug 15, 2023 | Naos Yaron Sr. VP, Operations | Award | 187,344 | — | Form 4 |
| Jan 3, 2023 | Schwartz Aharon Director | Purchase | 110,000 | $156K | Form 4 |
| Apr 11, 2022 | Bashan Dror President and CEO | Purchase | 68,000 | $102K | Form 4 |
| Feb 25, 2022 | Rubin Eyal Sr. VP and CFO | Award | 121,951 | — | Form 4 |
| Feb 25, 2022 | Bashan Dror President and CEO · Director | Award | 637,531 | — | Form 4 |
| Jun 2, 2021 | Dexcel Pharma Technologies Ltd. 10 percent owner | Sale | 61,211 | $157K | Form 4 |
Bashan Dror
PRESIDENT AND CEO · Director
日期
Dec 19
股数
56,000
均价
$1.81
总金额
$101K
Dexcel Pharma Technologies Ltd.
10 percent owner
日期
Jun 2
股数
61,211
均价
$2.56
总金额
$157K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 PLX 内幕交易
PLX 内幕交易
Protalix BioTherapeutics, Inc.（PLX）内幕交易数据来源于公司内部人（包括Bashan Dror (PRESIDENT AND CEO · Director), Bar-Shalev Amos (Director), Schwartz Aharon (Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。PLX内部人近期买卖活动混合，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Protalix BioTherapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
PLX 内幕交易 · 5个问题Protalix BioTherapeutics, Inc.（PLX）的内部人包括高管和董事，如Bashan Dror (PRESIDENT AND CEO · Director), Bar-Shalev Amos (Director), Schwartz Aharon (Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026